New drug duo shows promise in shrinking hard-to-treat colon tumors before surgery
NCT ID NCT05706779
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tests whether giving two targeted drugs (encorafenib and cetuximab) before surgery can shrink tumors in people with a specific genetic mutation (BRAF V600E) in localized colon or upper rectal cancer. About 30 participants will receive the drug combination for a short time before their planned surgery. The goal is to see how many tumors shrink significantly, which could lead to better surgical outcomes and lower the chance of the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu - Hôpital Européen Georges Pompidou
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.